Jacob Michael Rowe, M.D., F.A.C.P.
Dr. Rowe holds undergraduate and medical degrees from University College and University College Hospital in London. Currently, he is the chief of the Department of Hematology at the Shaare Zedek Medical Center in Jerusalem. He holds this position since 2011.
At the beginning of his career, he passed a fellowship in hematology/oncology at the University of Rochester, NY, and completed his internship in London. Throughout his career, Dr. Rowe was chief of many medical departments. Clinical Services of the Hematology Unit at the University of Rochester Medical Center, Rochester, NY between 1981 and 1996 for example, as well as the founding Director of the Bone Marrow Transplant Program at the University of Rochester. In 1994 Dr. Rowe became the Chief of the Department of Hematology and Bone Marrow Transplantation at the Rambam Medical Center, Haifa, Israel. He also was the incumbent Dresner Professor of Hemato-oncology at the Bruce Rappaport Faculty of Medicine of the Technion, Israel Institute of Technology, and is today Emeritus Professor at the Technion. Additionally, he holds an adjunct professorship at the Department of Medicine of Northwestern University, Chicago, IL. In 2014 he also received an honorary doctorate from the University of Gothenburg, Sweden.
Dr. Rowe took an active part in a wide range of national and international research projects and initiatives. As one of the two performing doctors, Dr. Rowe is the one to make the decision, if a patient can get the HSCT for MS treatment or not. Dr. Rowe is the head of the technical part, as he likes to say.
Dr. Rowe believes in the HSCT for MS treatment, he is convinced by the benefits of the procedure for multiple sclerosis patients and as one of the first physicians, he performed this treatment. Currently, he is the only physician who performs HSCT for MS in Israel.
Ariel Miller, MD, PhD
Dr. Ariel Miller has been a senior neurologist since 1989. Currently, he is the chief of the Center for Multiple Sclerosis and Brain Research at Carmel Medical Center in Haifa, Israel. He holds an M.D. degree from the ´Sackler` school of Medicine in Tel Aviv, as well as a Ph.D. degree in experimental Sciences from the Hebrew University of Jerusalem, Israel.
During the start of his career, Prof Miller was a research fellow at the center for neurologic diseases at Brigham and Woman’s Hospital, Harvard Medical school in Boston as a scholar of the Fogarty International Research Fellowship from 1989 to 1992. Additionally, he was working as a scientist in the department of cell biology at the Weizman Institute of Science in Rehovot, Israel from 1992 to 1993.
Today he is also an elected member of the American Neurological Association and a recipient of the Hershel Rich Technion Innovation Award – 2006 for his contribution in the field of pharmacogenetics and personalized medicine. His whole scientific and medical work is dedicated to elucidation of mechanisms underlying brain diseases, with a special focus on implementation of therapeutic strategies for Multiple Sclerosis as well as Pharmacogenetics towards developments of personalized medicine.
In our physician team, Prof. Miller is the head of neurology. He is the one, who is checking the neurological conditions and the qualifications of the patient for this treatment. He believes in looking into each case specifically, rather than formulating general cut-off criteria.
Together with Prof. Rowe, he is offering the HSCT for MS treatment based on his whole life researches, knowledge, and experiences with multiple sclerosis patients.